Empasug -M 500/5

Description:

• Empasug-M 500/5 is a fixed-dose combination of empagliflozin (5 mg) and metformin (500 mg). It delivers dual glucose-lowering benefits through complementary pathways—renal glucose excretion and hepatic glucose suppression. This tablet is indicated as an adjunct to diet and exercise in adults with T2DM.
• We are a certified empagliflozin 5mg tablet manufacturer and trusted name in combination therapy formulations.
• Being a prominent metformin 500mg tablets manufacturer, we ensure consistency, efficacy, and regulatory adherence in every batch.
• Globally recognized as a dependable empagliflozin tablets supplier, our products meet the needs of modern diabetes care across regions.
• Preferred by leading diabetes drugs manufacturers and therapy providers for robust metabolic outcomes.
• We are also among top-rated metformin 500mg tablets suppliers, delivering unmatched quality in diabetes management solutions.

Key Features:

• Integrates SGLT2 inhibition (empagliflozin) with biguanide therapy (metformin)
• Improves insulin resistance and lowers fasting plasma glucose
• Provides metabolic and cardiovascular advantages
• Supports weight loss and reduction in systolic blood pressure
• Offers once-daily administration with enhanced patient adherence

Usage Guidelines:

• Take once daily with meals to minimize GI side effects
• Recommended for patients requiring escalation from monotherapy
• Periodic monitoring of renal function is essential

Safety Profile:

• Adverse effects may include gastrointestinal discomfort, urinary infections
• Avoid use in patients with lactic acidosis risk or renal insufficiency
• Not recommended in type 1 diabetes or during acute metabolic decompensation

Uses / Indications: Used in adults with type 2 diabetes mellitus (T2DM) to improve blood sugar control as an adjunct to diet and exercise. Combines SGLT2 inhibitor (Empagliflozin) and biguanide (Metformin) for enhanced glucose regulation. Not for type 1 diabetes or diabetic ketoacidosis.